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Objective. To evaluate associations between common vaginal infections and human papillomavirus (HPV). Study Design.D a t a
from up to 15 visits on 756 HIV-infected women and 380 high-risk HIV-uninfected women enrolled in the HIV Epidemiology
Research Study (HERS) were evaluated for associations of bacterial vaginosis, trichomoniasis, and vaginal Candida colonization
with prevalent HPV, incident HPV, and clearance of HPV in multivariate analysis. Results. Bacterial vaginosis (BV) was associated
with increased odds for prevalent (aOR = 1.14, 95% CI: 1.04, 1.26) and incident (aOR = 1.24, 95% CI: 1.04, 1.47) HPV and with
delayed clearance of infection (aHR = 0.84, 95% CI: 0.72, 0.97). Whereas BV at the preceding or current visit was associated with
incidentHPV,inanalternatemodelfortheoutcomeofincidentBV,HPVatthecurrent,butnotpreceding,visitwasassociatedwith
incident BV. Conclusion. These ﬁndings underscore the importance of prevention and successful treatment of bacterial vaginosis.
1.Introduction
Human papillomavirus (HPV) is the most common sexually
transmitted infection (STI) among young adult women,
and it plays a critical role in the development of cervical
cancer [1, 2]. Biologic susceptibility to HPV acquisition
and immune competence for clearance of an HPV infection
could be aﬀected by common, treatable vaginal infections
that disrupt the intricately balanced vaginal ecosystem and
its innate protective mechanisms against infection and
disease.Bacterialvaginosisandtrichomoniasisareassociated
with high levels of anaerobic microorganisms and their
byproducts, that can damage vaginal epithelium, degrade
cervicalmucus,andcleaveimmunoglobulinA[3–6].Despite
the similar eﬀects of bacterial vaginosis and trichomoniasis
on the vaginal environment, there is increasing evidence
only for an association between HPV and bacterial vaginosis,
albeit of unknown directionality [7–9]. Bacterial vaginosis
and trichomoniasis are categorized, along with vulvovaginal
candidiasis, under the somewhat misnomer of vaginitis.
Unlike bacterial vaginosis and trichomoniasis, studies on
vulvovaginal candidiasis are complicated by its lack of a
clear laboratory deﬁnition, since the etiologic agent may
exist as part of the commensal microbiota in healthy
women. Candida albicans is the most prevalent species in
most cases of asymptomatic colonization and vulvovaginal
candidiasis; however certain species of Candida are more
pathogenic than others and induce hyphae formation and
have enhanced proteolytic activity and antigen modulation,
enabling Candida to penetrate the mucosal surface and2 Infectious Diseases in Obstetrics and Gynecology
induce mucosal swelling, erythema, and exfoliation of cells
[10–12]. The role of vaginal infections in HPV pathogenesis
has been evaluated in primarily cross-sectional studies and
has yielded conﬂicting results [8, 9, 13–19]. The purpose
of the current study was to evaluate associations for vaginal
infections with prevalent HPV, incident HPV, and clearance
of HPV in a large, prospective cohort of HIV-infected and
high-risk, HIV-uninfected women.
2.MaterialsandMethods
The HIV Epidemiology Research Study (HERS) was a
longitudinal multi-site investigation of the biological, psy-
chological, and social eﬀects of HIV infection among US
women [20]. Brieﬂy, from April 1993 through January 1995,
871 HIV-infected women and 439 high-risk HIV-uninfected
women were enrolled at four study sites: Bronx, NY; Bal-
timore, MD; Detroit, MI; and Providence, RI. Institutional
review boards at each participating medical center and at
the Centers for Disease Control and Prevention approved
the study protocol. All participants gave informed consent
and agreed to HIV testing and counseling. Women aged 16–
55 years were eligible for participation if they had a history
of injection drug use or high-risk sexual behavior, were
ﬂuent in either English or Spanish, and if HIV-seropositive,
reported no history of clinical AIDS-deﬁning conditions. At
each study site, HIV-seronegative women were frequency
matched to HIV-seropositive women on HIV status (1:2
ratio) and HIV risk behavior (1:1, sexual behavior to
injection drug use). Women completed up to 15 study visits
scheduled 6 months apart that consisted of an interview,
physical and pelvic examination, and blood, urine, oral, and
cervicovaginal specimen collection.
HPV testing used polymerase chain reaction (PCR) to
amplify virus obtained by cervicovaginal lavage [21]. The
ampliﬁed product was identiﬁed by hybridization with a
generic HPV probe and probes speciﬁc to 26 HPV types: 6,
11, 16, 18, 26, 31, 33, 34, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56,
58, 59, 66, 68, 73, 82, 83, and 84. Samples with missing (n =
17) or negative (n = 72) test results for hybridization with
thecontrol,B-globinprobewereconsideredofunsatisfactory
quality, and the HPV results were set to missing.
For the purposes of the current analysis, visit-speciﬁc
prevalent HPV infection was deﬁned by detection of any
HPV DNA by general probe at a given visit. Incident
infection was deﬁned as detection of a new type of HPV not
present at any prior visit. Thus, HPV type-speciﬁc negative
women at enrollment were at risk for infection with the
respective HPV type. Women who were HPV-negative by
all type-speciﬁc probes and generic probe prior to testing
positive by generic probe only (i.e., untypable infection)
were classiﬁed as having incident HPV at that visit. For the
evaluation of time to HPV clearance, women contributed
event times for each incident HPV type. Time to clearance
was deﬁned as the interval from the type-speciﬁc incident
visit to the ﬁrst of two consecutive type-speciﬁc negative
visits. The ﬂagging negative visit was required to avoid
misclassiﬁcation from ﬂuctuating detection of HPV [22].
HPV infections that were followed by a single HPV-negative,
ﬁnal study visit were censored at that negative visit. HPV
infections that were positive at the last study visit had 6
months added to ensure comparability of assumptions about
clearance of HPV infection for censored and noncensored
observations. HPV infections spanning a single missing visit
were assumed to persist over the unobserved period.
Each vaginal infection was deﬁned using standard crite-
ria.PresenceofbacterialvaginosiswasdeterminedbyNugent
scoring of a gram-stained slide [23]. A Nugent score of 7
to 10 deﬁned bacterial vaginosis, whereas a score of 0 to 6
deﬁnednormal-intermediatevaginalﬂora.Forvisitswithout
aN u g e n ts c o r e( <1%), bacterial vaginosis was deﬁned by
modiﬁed Amsel’s criteria [23]. Presence of vaginal Candida
colonization was based on a positive culture for Candida
species or detection of yeast or pseudohyphae on gram stain.
Presence of trichomoniasis was determined by detection of
trichomonas on wet mount (all visits) or on culture (visits 4
and above).
Women were eligible for the current analysis if they
had baseline data on HPV DNA and bacterial vaginosis,
vulvovaginal candidiasis, or trichomoniasis test results (n =
1256). Of these women, 108 who did not have a cervix
at baseline and one woman who had cervical treatment
and a hysterectomy within 6 months before and after
enrollment, respectively, were excluded. For simplicity, an
additional11womenwhoseroconvertedtoHIV-seropositive
during follow-up were excluded, leaving 1136 subjects for
this analysis. Person-time was censored at the date of
cervical treatment (e.g., excisional biopsy, cryotherapy) or
hysterectomy for 111 subjects.
Potential confounders of the relationship between vagi-
nal infections and prevalent HPV, incident HPV, and clear-
ance of HPV were selected based on the literature and a
proposed causal directed acyclic diagram (not shown) used
for identiﬁcation of suﬃcient sets of confounders [24]. The a
priori model for prevalent HPV and incident HPV included
sexual risk factors (new or multiple male sex partners
and frequency of condom use), illicit drug use, cigarette
smoking, use of hormonal contraceptives, immunologic
predisposingfactors(HIVstatus,CD4count,andviralload),
and demographic indicators for HPV prevalence in the
USA (age, race, and socioeconomic status) [1, 25]. Ap r i o r i
models for time to HPV clearance also included a covariate
indicating coinfection with another HPV type within the
type-speciﬁc duration and its cancer risk classiﬁcation. All
statistical models included the study design variables: study
site and risk behavior cohort (sexual or injection drug use).
In addition, models included a covariate for visit number,
year of visit, or year of HPV onset to account for period
eﬀects.
In addition to the variables selected ap r i o r i , other
factors related to cervicovaginal health were evaluated in
bivariate and multivariable analysis using SAS versus 9.2
(SAS Institute Inc., Cary, NC). These factors included poten-
tial hormonal inﬂuences (e.g., pregnancy, postmenopausal
state, and estrogen replacement therapy), sexual behavior
(e.g., sexual frequency), genital tract infections (e.g., herpes
simplex virus-2 serostatus at baseline—culture and PCRInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Characteristics of 756 HIV-infected and 380 HIV-uninfected women at enrollment to HERS.
Characteristic HIV-infected n (%) HIV-uninfected n (%) P value
HIV risk category
Injection drug user 391 (51.7) 184 (48.4) 0.29
High sexual risk 365 (48.3) 196 (51.6)
Age
<24 53 (7.0) 38 (10.0) 0.27
25–34 351 (46.4) 173 (45.5)
35–44 310 (41.0) 144 (37.9)
45+ 42 (5.6) 25 (6.6)
Race/ethnicity
African American 457 (60.5) 200 (52.6) <0.01
Caucasian 155 (20.5) 117 (30.8)
Hispanic 135 (17.9) 59 (15.5)
Native American or Asian 9 (1.2) 4 (1.1)
Education
<H.S. 342 (45.4) 141 (37.3) 0.01
H.S. 249 (33.0) 130 (34.4)
>H.S. 163 (21.6) 107 (28.3)
Number of live births
0 126 (16.7) 79 (20.8) 0.22
1 171 (22.6) 78 (20.5)
≥2 459 (60.7) 223 (58.7)
Number of male sex partners in past 6 months
0 187 (24.9) 56 (14.9) <0.01
1 423 (56.3) 187 (49.7)
≥2 141 (18.8) 133 (35.4)
Lower genital tract infections
Bacterial vaginosis 361 (47.8) 164 (43.2) 0.14
Vaginal Candida colonization 273 (36.2) 82 (21.6) <0.01
Trichomonas vaginalis 96 (12.8) 40 (10.6) 0.29
Chlamydia trachomatis 8 (1.4) 5 (1.6) 0.98
Neisseria gonorrhoeae 6 (0.8) 1 (0.3) 0.28
Herpes simplex virus-2 antibodies 491 (66.7) 207 (56.0) <0.01
Genital ulcers 60 (7.9) 16 (4.2) 0.02
Human papillomavirus
Generic probe positive 482 (63.7) 109 (28.7) <0.01
Untypeable 98 (20.3∗) 33 (30.3∗)0 . 0 2
1 type 204 (42.3∗) 56 (51.4∗) <0.01
2 types 96 (19.9∗) 13 (11.9∗)
≥3 types 84 (17.4∗)7 ( 6 . 4 ∗)
Hepatitis C 443 (59.0) 178 (47.3) <0.01
Recent crack cocaine or injection drug use 285 (37.7) 166 (43.7) 0.05
Cigarette smoker 566 (74.9) 294 (77.4) 0.35
HIV disease progression
CD4+ lymphocyte count (cells/µL) n/a
<200 130 (17.3)
200–499 378 (50.3)
≥500 243 (32.4)4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Continued.
Characteristic HIV-infected n (%) HIV-uninfected n (%) P value
HIV RNA load (copies/mL) n/a
≥10,000 143 (19.3)
3,000–<10,000 124 (16.8)
500–<3,000 287 (38.8)
<500 186 (25.1)
Antiretroviral therapy n/a
None 500 (66.1)
Sub-HAART† 256 (33.9)
HIV: human immunodeﬁciency virus; RNA: ribonucleic acid.
n (%) = number of subjects and percent of HIV-infected or HIV-uninfected cohort.
∗Percent of those who were generic probe positive.
†Sub-HAARTwasdeﬁnedasself-reporteduseofanyantiretroviral(s)thatcombineddonotqualifyashighlyactiveantiretroviraltherapy(HAART)according
to the Department of Health and Human Services guidelines [26].
Table 2: Odds ratios for prevalent human papillomavirus among all HERS women and by HIV status.
Vaginal infection
HERS overall HIV infected1 HIV uninfected2
(8920 visits) (5869 visits) (3051 visits)
aOR (95% CL) aOR (95% CL) aOR (95% CL)
Bacterial vaginosis 1.14 (1.04, 1.26) 1.15 (1.03, 1.29) 1.18 (0.98, 1.42)
Trichomonas vaginalis ∗ 1.16 (0.91, 1.49)
Among Candida colonization+ 1.05 (0.84, 1.32)
Among Candida colonization - 0.75 (0.62, 0.90)
Vaginal Candida colonization ∗ 1.12 (0.93, 1.35)
Among Trichomonas vaginalis+ 1.36 (1.05, 1.75)
Among Trichomonas vaginalis− 0.97 (0.87, 1.08)
HIV: human immunodeﬁciency virus.
aOR (95% CL) = adjusted odds ratio and 95 percent conﬁdence limits.
Generalizedlinearmixedmodelswithrandominterceptandslopebasedonthetoeplitzmatrixwereadjustedforstudysite,riskbehaviorcohort,visitn umbe r ,
age group, race/ethnicity, cigarette smoking, illicit drug use, new or multiple male sex partners, and consistency of condom use. Model for HIV-infected
women was also adjusted for CD4 group (<200, 200–500, and >500cells/µL) and logarithm of viral load.
1Statistical interaction between trichomoniasis and vaginal Candida colonization (P = 0.014).
2No statistical interactions detected at the P<0.15 level.
∗NooddsratiosarepresentedfortheoverallHERScohortbecauseHIVstatussigniﬁcantlymodiﬁedtheassociationsbetweentrichomoniasis,vaginalCandida
colonization, and HPV prevalence.
testing for chlamydia and gonorrhea ceased after the third
study visit due to very low frequency in this population),
and other risk behaviors or conditions (e.g., alcohol drinking
and hepatitis C serostatus at baseline). The importance of
a covariate was evaluated in terms of the causal directed
acyclic graph, collinearity with other covariates, and its
coeﬃcient magnitude, statistical signiﬁcance, and impact on
the eﬀect estimates for vaginal infections upon addition to
and removal from the statistical model.
A generalized linear mixed model with a random
intercept and a slope based on a toeplitz matrix was used
to model associations between current vaginal infections
and prevalent HPV while accounting for between-subject
variation and repeated measures correlation. To evaluate
associations between vaginal infections at the preceding visit
andincidentHPV,aswellastoexplorethetemporalrelation-
shipbetweenHPVandbacterialvaginosis,thecase-crossover
analytic approach was used. The case-crossover approach
is useful for identifying associations between recent, time-
varying exposures and an incident outcome while adjusting
for all time-independent factors by comparing each woman’s
case (e.g., incident HPV) visits to her own noncase visits.
To evaluate temporality, separate case-crossover models were
run for incident HPV and incident bacterial vaginosis that
were adjusted for a few shared time-dependent predictors:
a combined indicator for HIV status and CD4 category
(with 4 categories: HIV-negative and HIV-positive with
CD4 > 500, CD4 200–500, and CD4 < 200) and self-
reported crack or cocaine use, new or multiple sex partners,
and consistency of condom use since the prior study
visit.
Analyses of time to clearance of a type-speciﬁc HPV
infection used the Wei, Lin, and Weissfeld extended Cox
model. Hazard ratios less than 1.0 indicate lower clearance
rates (i.e., longer duration of infection). Vaginal infections,
and most of the covariates, were modeled as time-dependentInfectious Diseases in Obstetrics and Gynecology 5
variables allowing the instantaneous eﬀects to vary with
changes in the time-dependent variables.
Upon ﬁnalizing the main eﬀects models, modiﬁcation
of the eﬀect estimates for vaginal infections across levels of
biologically relevant covariates (e.g., HIV status, concurrent
vaginal infections) was evaluated for magnitude and signif-
icance (P<0.15) using the Wald and Likelihood Ratio
tests. Due to eﬀect measure modiﬁcation of the association
between certain vaginal infections and HPV outcomes by
HIV status, tabular results are presented separately for HIV-
infected and HIV-uninfected women.
3. Results
At baseline, HIV-infected women (n = 756) were similar
to HIV-uninfected women (n = 380) in age, number
of live births, cigarette smoking status, and prevalence of
bacterial vaginosis, trichomonas vaginalis, Chlamydia tra-
chomatis,a n dNeisseria gonorrhoeae infections (Table 1). The
HIV-uninfected women were more likely to have recently
used crack cocaine or injection drugs and had multiple
sex partners in the prior 6 months. The HIV-infected
women were more likely to be of African American race, of
lower educational level, and seropositive for hepatitis C and
herpes simplex 2. HIV-infected women were also more likely
to be vaginally colonized with Candida species and have
detectableHPV.TheprevalenceofHPVamongHIV-infected
women(64%)wasovertwicethatofHIV-uninfectedwomen
( 2 9 % ) ,a n dH I V - i n f e c t e dw o m e nw e r em o r el i k e l yt ob e
coinfected with multiple HPV strains (Table 1). However,
among women with HPV, the proportion with untypable
HPV infections was greater among HIV-uninfected women
(30.3%) than among HIV-infected women (20.3%). At
enrollment, most of the HIV-infected women (83%) had
CD4 counts above 200cells/µL. Enrollment was completed
before the onset of the highly active antiretroviral therapy
(HAART) era, so none of the women were on HAART
regimensatbaseline.However,one-thirdoftheHIV-infected
women were taking antiretrovirals.
The prevalence of HPV infection at visits 1–15 ranged
from 38% to 56% (49–68% for HIV-infected women and
12–32% for HIV-uninfected women). Longitudinal, multi-
variable analysis for prevalent HPV demonstrated a strong
association with HIV status and immunodeﬁciency. HIV-
infected women with CD4 cell counts below 200 cells/µLh a d
greater odds for prevalent HPV compared to HIV-infected
women with CD4 counts above 500 cells/µL (adjusted odds
ratio (aOR) = 1.53, 95% CI: 1.25, 1.86). There was no
modiﬁcation of the odds ratio for bacterial vaginosis on
prevalent HPV by HIV status (Table 2). In a model adjusted
for a combined indicator of HIV status and CD4 group,
bacterialvaginosiswassigniﬁcantlyassociatedwithincreased
odds for prevalent HPV among all HERS women (aOR =
1.14, 95% CI: 1.04, 1.26). HIV status signiﬁcantly modiﬁed
the associations among trichomoniasis, vaginal Candida
colonization, and HPV prevalence. In a model for HIV-
uninfected women, there was no signiﬁcant association for
trichomoniasis or vaginal Candida colonization with preva-
lent HPV (Table 2). However, among HIV-infected women,
there was a signiﬁcant interaction between trichomoniasis
and vaginal Candida colonization: trichomoniasis was sig-
niﬁcantly associated with decreased odds for prevalent HPV
among women without vaginal Candida colonization, and
vaginal Candida colonization was signiﬁcantly associated
with increased odds for prevalent HPV among women with
trichomoniasis (Table 2). When vaginal Candida coloniza-
tion was removed from the model, trichomoniasis remained
signiﬁcantly associated with decreased odds for prevalent
HPV among the HIV-infected women (aOR = 0.85, 95% CI:
0.73, 0.98). In contrast, when trichomoniasis was removed
from the model, vaginal Candida colonization was not
associated with prevalent HPV (aOR = 1.02, 95% CI: 0.92,
1.12).
Incident HPV infections occurred at 14% of follow-up
visits (17.4% among HIV-infected women and 7.5% among
high-risk, HIV-uninfected women). There was no modiﬁca-
tionoftheoddsratioforpriorbacterialvaginosisonincident
HPV by HIV status (Table 3). In a model adjusted for a
combined indicator of HIV status and CD4 group, bacterial
vaginosis at the preceding visit was signiﬁcantly associated
with 24% increased odds for incident HPV among all HERS
women (aOR = 1.24, 95% CI: 1.04, 1.47) (Table 3). Bacterial
vaginosis at the current visit was similarly associated with
incidentHPV(aOR =1.25,95%CI:1.05,1.48).Incontrast,a
case-crossover analysis for the outcome of incident bacterial
vaginosis found that HPV at the current visit (aOR = 1.46,
95% CI: 1.12, 1.90), but not at the preceding visit (aOR =
1.05, 95% CI: 0.80, 1.37), was predictive of incident bacterial
vaginosis among all women. Trichomoniasis and vaginal
Candida colonization was not signiﬁcantly associated with
incident HPV, regardless of timing of vaginal infection
relevant to HPV infection (Table 3).
The majority of incident HPV infections cleared over
subsequent study visits (63.1% clearance among HIV-
infectedwomenand74.8%among HIV-uninfectedwomen).
Among HIV-infected women, those with CD4 counts below
200cells/µL were half as likely to clear an HPV infection as
those with CD4 counts above 500cells/µL (adjusted hazards
ratio (aHR) = 0.51, 95% CI: 0.40, 0.64). HIV status and CD4
category did not signiﬁcantly modify the hazard ratios for
vaginal infections with HPV clearance. However, there was a
statistical interaction between bacterial vaginosis and vaginal
Candida colonization (Table 4). Among all HERS women
with vaginal Candida colonization, bacterial vaginosis was
associated with a lower rate of HPV clearance (aHR =
0.65, 95% CI: 0.51, 0.83), and vice versa, among women
with bacterial vaginosis, vaginal Candida colonization was
associated with delayed HPV clearance (aHR = 0.73, 95% CI:
0.58,0.93).WhenvaginalCandidacolonizationwasremoved
from the model, bacterial vaginosis remained signiﬁcantly
associated with delayed clearance of HPV among all HERS
women (aHR = 0.84, 95% CI: 0.72, 0.97). In contrast,
when bacterial vaginosis was removed from the model,
vaginal Candida colonization was not associated with HPV
clearance (aHR = 0.93, 95% CI: 0.81, 1.08). We did not
detect a signiﬁcant association between trichomoniasis and
time to clearance of HPV infection, regardless of HIV status
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Table 3: Odds ratios for incident human papillomavirus among all HERS women and by HIV status.
Vaginal infection at prior visit
HERS overall HIV infected HIV uninfected
(5587 visits) (4038 visits) (1549 visits)
aOR (95% CL) aOR (95% CL) aOR (95% CL)
Bacterial vaginosis 1.24 (1.04, 1.47) 1.22 (1.00, 1.50) 1.22 (0.84, 1.77)
Trichomonas vaginalis 1.05 (0.84, 1.32) 1.11 (0.86, 1.44) 0.86 (0.53, 1.40)
Vaginal Candida colonization 0.97 (0.82, 1.15) 1.04 (0.86, 1.26) 0.75 (0.51, 1.11)
HIV: human immunodeﬁciency virus.
aOR (95% CL) = adjusted odds ratio and 95 percent conﬁdence limits.
Conditionallogisticregressionmodelswereadjustedforthefollowingtime-varyingfactors:illicitdruguse,newormultiplemalesexpartners,andconsistency
of condom use since the last study visit. Model for HIV-infected women was also adjusted for CD4 group (<200, 200–500, and >500cells/µL) and logarithm
of viral load.
Table 4: Hazard ratios for type-speciﬁc clearance of human papillomavirus among all HERS women and by HIV status.
Vaginal infection
HERS overall HIV infected HIV uninfected
(1230 HPV infections) (1016 HPV infections) (214 HPV infections)
aHR (95% CL) aHR (95% CL) aHR (95% CL)
Trichomonas vaginalis 1.06 (0.88, 1.27) 1.12 (0.91, 1.36) 1.00 (0.56, 1.78)
Bacterial vaginosis
Among Candida colonization + 0.65 (0.51, 0.83) 0.71 (0.55, 0.94) 0.38 (0.16, 0.87)
Among Candida colonization− 0.96 (0.79, 1.15) 0.94 (0.75, 1.17) 1.25 (0.77, 2.05)
Vaginal Candida colonization
Among bacterial vaginosis+ 0.73 (0.58, 0.93) 0.76 (0.59, 0.99) 0.41 (0.17, 0.96)
Among bacterial vaginosis− 1.07 (0.89, 1.28) 1.00 (0.81, 1.24) 1.36 (0.85, 2.18)
HIV: human immunodeﬁciency virus; HPV: human papillomavirus.
aHR (95% CL) = adjusted hazards ratio and 95 percent conﬁdence limits.
Wei, Lin, and Weissfeld extended Cox models were adjusted for study site, risk behavior cohort, visit year at onset of HPV infection, age group, race/ethnicity,
cigarette smoking, new or multiple male sex partners, consistency of condom use, coinfection with another HPV type, and its cancer risk classiﬁcation. Model
for HIV-infected women was also adjusted for CD4 group (<200, 200–500, and >500cells/µL) and logarithm of viral load.
Statistical interaction between trichomoniasis and vaginal Candida colonization (HIV-infected model: P = 0.111; HIV-uninfected model: P = 0.018).
4. Comment
Consistent with a recent meta-analysis of primarily cross-
sectional studies, bacterial vaginosis was associated with
increased odds for prevalent HPV among women in HERS
[7]. Furthermore, in this large, prospective study, bacterial
vaginosis was associated with increased odds for incident
HPV and delayed clearance of HPV. The former ﬁnding is
consistent with a reported increase in HPV incidence among
women with bacterial vaginosis in the Women’s Interagency
HIV Study (WIHS) [9]. Prior attempts to decipher the
temporal relationship between bacterial vaginosis and HPV
yielded conﬂicting ﬁndings [8, 9]. In this study, bacterial
vaginosis, whether considered at the preceding or current
visit, was associated with incident HPV, whereas, in an
alternate multivariable model for the outcome of incident
bacterial vaginosis, only HPV at the current visit was
signiﬁcant. These ﬁndings are in accord with biologic plau-
sibility since, unlike most cervical HPV infections, bacterial
vaginosis causes major changes in the local environment
leading to degradation of innate defenses.
While trichomoniasis infection was not signiﬁcantly
associated with HPV outcomes among HIV-uninfected
women in HERS, HIV-infected women with trichomoniasis
had decreased odds for prevalent HPV. A similar ﬁnding was
reported from a WIHS analysis which combined 1736 HIV-
infected and 493 HIV-uninfected women into one analytic
group [9]. In that study, detection of trichomoniasis on
wet mount was associated with lower prevalence, increased
incidence, and shorter duration of HPV infection. In the
current study, we did not detect a signiﬁcant eﬀect of
trichomoniasis on incident HPV or clearance of infec-
tion; however, this may have been due to lower statistical
power. Smaller studies among only HIV-uninfected women
are more consistent with our ﬁndings among the HIV-
uninfected women in suggesting absence of an association
betweentrichomoniasisandprevalent,incident,orpersistent
HPV [14, 15, 18]. The apparent diﬀerence by HIV status
in associations for trichomoniasis with HPV prevalence
and duration may be attributable to the strong eﬀect of
HIV on duration of HPV infection relative to the mini-
mal, if any, eﬀect of HIV on duration of trichomoniasis.
Explicitly, as the duration of HPV infection increases, the
proportion of HPV-positive visits that have trichomoniasis
present decrease, giving the appearance of a protective
association.
The presence of vaginal Candida colonization alone was
not signiﬁcantly associated with HPV outcomes; howeverInfectious Diseases in Obstetrics and Gynecology 7
when concurrent with bacterial vaginosis or trichomoniasis,
itnegativelyimpactedtheireﬀectsoncertainHPVoutcomes.
The decreased odds for prevalent HPV among women with
trichomoniasiswasnotobservedamongwomenwithvaginal
Candida colonization, and the association between bacterial
vaginosis and delayed clearance of an HPV infection was
strongest among women with vaginal Candida colonization.
Standard antibiotic treatment for bacterial vaginosis or
trichomoniasis may precipitate a vaginal yeast infection,
and a high incidence of asymptomatic and symptomatic
vulvovaginal yeast infection has been reported in patients
with recurrent bacterial vaginosis [27]. Therefore, concur-
rent vaginal Candida colonization may indicate more severe
or diﬃcult-to-treat bacterial vaginosis or trichomoniasis.
The HERS cohort, two-thirds of which are HIV-infected,
represents a population at increased risk for vaginal infec-
tions and HPV. As such, there are two primary concerns
regarding these study’s ﬁndings: (1) the potential depen-
dency of the results on HIV disease and (2) the generaliz-
ability of the results to the general population of women.
Several methods were used to reduce potential confounding
of the relationships between vaginal infections and HPV by
HIV-associated factors: (1) by design, HIV-infected women
were frequency matched at enrollment to HIV-uninfected
women on sexual and injection drug use behavior, (2) self-
reported risk behavior between study visits was included in
multivariable analyses, (3) models among all HERS women
were evaluated for statistical interaction with a composite
variable of HIV status and CD4 count, and (4) separate
models were built for HIV-infected and HIV-uninfected
women, with the former adjusted for CD4 category and
logarithm of viral load. Despite these eﬀorts, disentangling
the interrelationships between HIV disease and concurrent
vaginal infections was limited by decreased statistical power
to detect signiﬁcant associations among HIV-uninfected
women separately. While the HERS cohort is a population
at high-risk for genital tract infections, the primary ﬁndings
involve two infections for which the general female popula-
tion is also at high risk: bacterial vaginosis and HPV. More-
over, there is mounting evidence for an association between
bacterialvaginosisandHPVacrossdiversestudypopulations
[7].
This is the second large, prospective study among HIV-
infected and HIV-uninfected women to report consistent
ﬁndings for bacterial vaginosis with increased prevalent
and incident HPV [9]. In the current study, bacterial
vaginosis was also associated with delayed clearance of
HPV infection. While there is mounting evidence for
an association between bacterial vaginosis and HPV, a
temporal association has remained unclear [7–9]. In the
current study, we found that bacterial vaginosis, whether
considered at the preceding or current study visit, was
associated with incident HPV, whereas HPV at the cur-
rent, but not preceding, visit was associated with incident
bacterial vaginosis. In summary, the current study suggests
bacterial vaginosis may predispose a woman to HPV infec-
tion and delayed HPV clearance, underscoring the impor-
tance of prevention and successful treatment of bacterial
vaginosis.
Condensation
Bacterial vaginosis is associated with increased odds for
prevalent and incident HPV as well as delayed clearance
among women in the HIV Epidemiology Research Study.
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